VOL 37 Supplement No. 1

INTRODUCTION

Advancing the Treatment of Mood and Anxiety Disorders: The First 10 Years’ Experience with Paroxetine

Charles B. Nemeroff, MD, PhD

The last half of the 20th century witnessed remarkable advances in psychiatry that began with serendipity and were realized through the combined efforts of astute clinical observation, scientific investigation, and patient advocacy. The modern era...

Pages 6-7 Read Article

Neuropharmacology of Paroxetine

Michael J. Owens, PhD, and Charles B. Nemeroff, MD, PhD

Paroxetine is a potent and selective serotonin reuptake inhibitor (SSRI) with some neuropharmacologic properties unique among this class of compounds. Early in vitro studies demonstrated the potency of paroxetine at inhibiting 5-HT uptake in rat...

Pages 8-18 Read Article

In Vivo Neuroimaging Correlates of the Efficacy of Paroxetine in the Treatment of Mood and Anxiety Disorders

Clinton Kilts, PhD

The advent of neuroimaging technology has brought a deeper understanding of brain function and structure in health and psychiatric illness. This article overviews pertinent findings from neuroimaging studies in mood and anxiety disorders. Paroxetine is...

Pages 19-28 Read Article

Pharmacokinetics, Drug Interactions, and Tolerability of Paroxetine and Paroxetine CR

C. Lindsay DeVane, PharmD

The development of paroxetine hydrochloride began in the late 1970s. An abundance of data has been accumulated from clinical investigations demonstrating the efficacy of paroxetine in the treatment of major depression and anxiety disorders. The...

Pages 29-40 Read Article

Paroxetine Treatment of Major Depressive Disorder

Martin B. Keller, MD

Major depression is recognized as a common, often chronic and recurrent illness associated with significant disability and comorbidity. The treatment of patients with major depressive disorder has advanced tremendously in the past decade due to...

Pages 42-52 Read Article

Treatment of Panic Disorder: Focus on Paroxetine

Mark H. Pollack, MD and Alicia C. Doyle, BA

Panic disorder is a chronic and disabling condition associated with significant morbidity. Treatment of panic disorder has evolved significantly in the past 20 years with the availability of serotonergic antidepressants, including the selective serotonin reuptake...

Pages 53-62 Read Article

Paroxetine Treatment of Generalized Anxiety Disorder

David V. Sheehan, MD, MBA, and C. Gloria Mao, PharmD

Generalized anxiety disorder (GAD) is a prevalent and disabling anxiety disorder, conservatively believed to affect at least 5% of the general population. Cardinal symptoms of GAD include chronic and uncontrollable worry, anxiety, and tension, which...

Pages 64-74 Read Article

Treatment of Posttraumatic Stress Disorder: The Impact of Paroxetine

Jonathan R.T. Davidson, MD

The past decade has seen remarkable advances in our ability to treat patients with posttraumatic stress disorder (PTSD). In addition, we are now much more aware of the prevalence of PTSD in civilian populations, and...

Pages 76-88 Read Article

Obsessive-Compulsive Disorder: Implications of the Efficacy of an SSRI, Paroxetine

Philip T. Ninan, MD

Obsessive-compulsive disorder (OCD) is an anxiety disorder that commonly presents comorbidly with other psychiatric disorders. The underlying neurobiology of OCD is associated with circuits involving the basal ganglia, thalamus, and the frontal cortex. Randomized, placebo-controlled...

Pages 89-96 Read Article

Advances in Recognition and Treatment of Social Anxiety Disorder: A 10-Year Retrospective

Murray B. Stein, MD, FRCPC

Social anxiety disorder frequently begins in early life and is associated with the subsequent development of comorbid conditions such as depressive and substance use disorders. Social anxiety disorder, particularly the generalized subtype, is characterized by...

Pages 97-107 Read Article

Paroxetine Use in Medically Ill Patients

Steven Stout, MD, PhD; Wendy I. Somerset, MD; Andrew Miller, MD; and Dominique L. Musselman, MD, MS

Depression is a highly prevalent disorder in the adult population and often worsens the prognosis of comorbid medical illnesses. Recent research has illuminated biological mechanisms by which psychiatric and medical illnesses, as well as their...

Pages 108-120 Read Article

Paroxetine Treatment of Depression in Late Life

Charles F. Reynolds III, MD

The elderly population is growing at a rapid rate and currently constitutes more than 12% of the United States’ population. Within the next 30 years, the number of elderly persons is expected to more than...

Pages 123-134 Read Article

Paroxetine Treatment of Mood Disorders in Women: Premenstrual Dysphoric Disorder and Hot Flashes

Kimberly A. Yonkers, MD

With the relatively recent introduction of the selective serotonin reuptake inhibitor (SSRI) class of antidepressants, increased attention has been focused on the use of antidepressants in the treatment of mood disorders across the female life...

Pages 135-147 Read Article

Clinical Management of Perinatal Depression: Focus on Paroxetine

D. Jeffrey Newport, MD, MSCR, MDiv, and Zachary N. Stowe, MD

The literature on antidepressant use during pregnancy and lactation is replete with review articles and clinical decision algorithms. Remarkably, a limited number of such articles include the methodological advances that have served to define the...

Pages 148-164 Read Article

Paroxetine Treatment of Mood and Anxiety Disorders in Children and Adolescents

Karen Dineen Wagner, MD, PhD

This article provides an overview of the use of paroxetine in the treatment of mood and anxiety disorders in children and adolescents. Although not currently approved for use in patients younger than 18 years of...

Pages 167-175 Read Article

Efficacy and Tolerability of Controlled-Release Paroxetine

Robert N. Golden, MD

Paroxetine controlled-release (CR) was developed with the objective of minimizing the occurrence and severity of selective serotonin reuptake inhibitor (SSRI)-associated adverse events, thereby improving clinical outcomes. Paroxetine CR delays the onset and controls the rate...

Pages 176-186 Read Article